Novo’s Big Game spot can help reinforce the Wegovy pill’s credibility against copycat compounded versions.
Midi Health’s growth shows sustained focus on women’s care can fuel digital health trust and scale.
An FTC settlement and newly passed legislation in Congress scraps rebate tactics and formulary bias, chipping away at PBM pricing power.
Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.
Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.
Most Americans are wary of their use in healthcare, but supervised medical use is starting to feel acceptable.
Costs will shape 2026 midterm votes, with both parties targeting insurers and pharma to lower costs. The industry has a chance to defend its role—and show real affordability gains.
But a crowded obesity market demands product differentiation, fewer side effects, and benefits beyond weight loss to reap financial gains.
The UK-based pharma giant lists its stock on NYSE even as it continues overseas manufacturing and innovation spending.
Pharma and health brands return to the Super Bowl, ditching drug pitches for brand storytelling campaigns.
D2C pharma brands must ensure their cash-pay programs and telehealth ties are transparent and compliant with anti-kickback laws.
Better-staffed pharmacies could become Walmart’s edge, even as more consumers move online.
Studies link higher AFib detection to watch wearers, strengthening wearables’ medical case.
Novo’s oral drug is wildly outperforming weekly sales needed to hit forecasts, signaling strong early demand for GLP-1 pills.
Rising demand clashes with high costs, no insurance coverage, and doctors’ reluctance to validate outside results.
The revenue hit to pharma should be modest, but drug-pricing headwinds will force manufacturers to trade margin for volume and push harder on prices abroad.
More than one-third of Gen Z and millennials turn to AI for stigma-free support.
Benefits emerge with adherence, increasing pressure on employers to keep coverage.
Health and wellness is the only category where plans to increase spending outweigh plans to cut back in 2026, according to December 2025 data from CivicScience. That’s why retailers are stepping up their investments in wellness-driven products, services, and in-store experiences, trying to capitalize on consumers’ resolutions well into the new year.
Clinicians and staff adopt “shadow AI” tools to move faster, exposing gaps in hospital AI strategy.